By F. Navaras. The Johns Hopkins University.
Primary rating instruments used for assessing manic symptoms in these trials were: (1) the Mania Rating Scale (MRS) purchase accutane 5mg otc, which is derived from the Schedule for Affective Disorders and Schizophrenia- Change Version (SADS-CB) with items grouped as the Manic Syndrome subscale (elevated mood discount accutane 10mg fast delivery, less need for sleep 20mg accutane with amex, excessive energy, excessive activity, grandiosity), the Behavior and Ideation subscale (irritability, motor hyperactivity, accelerated speech, racing thoughts, poor judgment) and impaired insight; and (2) the Clinical Global Impression -Severity of Illness Scale (CGI-S), which was used to assess the clinical significance of treatment response. The results of the oral ziprasidone trials in bipolar mania follow: (1) In a 3-week placebo-controlled trial (n=210), the dose of ziprasidone was 40 mg BID on Day 1 and 80 mg BID on Day 2. Titration within the range of 40-80 mg BID (in 20 mg BID increments) was permitted for the duration of the study. Ziprasidone was significantly more effective than placebo in reduction of the MRS total score and the CGI-S score. The mean daily dose of ziprasidone in this study was 132 mg. Titration within the range of 40-80 mg BID (in 20 mg BID increments) was permitted for the duration of study (beginning on Day 2). Ziprasidone was significantly more effective than placebo in reduction of the MRS total score and the CGI-S score. The mean daily dose of ziprasidone in this study was 112 mg. Acute Agitation in Schizophrenic Patients The efficacy of intramuscular ziprasidone in the management of agitated schizophrenic patients was established in two short-term, double-blind trials of schizophrenic subjects who were considered by the investigators to be "acutely agitated" M and in need of IM antipsychotic medication. In addition, patients were required to have a score of 3 or more on at least 3 of the following items of the PANSS: anxiety, tension, hostility and excitement. Efficacy was evaluated by analysis of the area under the curve (AUC) of the Behavioural Activity Rating Scale (BARS) and Clinical Global Impression (CGI) severity rating. The BARS is a seven point scale with scores ranging from 1 (difficult or unable to rouse) to 7 (violent, requires restraint). There were few patients with a rating higher than 5 on the BARS, as the most severely agitated patients were generally unable to provide informed consent for participation in pre-marketing clinical trials. Both studies compared higher doses of ziprasidone intramuscular with a 2 mg control dose. In one study, the higher dose was 20 mg, which could be given up to 4 times in the 24 hours of the study, at interdose intervals of no less than 4 hours. In the other study, the higher dose was 10 mg, which could be given up to 4 times in the 24 hours of the study, at interdose intervals of no less than 2 hours. The results of the intramuscular ziprasidone trials follow: (1) In a one-day, double-blind, randomized trial (n=79) involving doses of ziprasidone intramuscular of 20 mg or 2 mg, up to QID, ziprasidone intramuscular 20 mg was statistically superior to ziprasidone intramuscular 2 mg, as assessed by AUC of the BARS at 0 to 4 hours, and by CGI severity at 4 hours and study endpoint. Ziprasidone is indicated for the treatment of schizophrenia. Prolongation of the QTc interval is associated in some other drugs with the ability to cause torsade de pointes-type arrhythmia, a potentially fatal polymorphic ventricular tachycardia, and sudden death. In many cases this would lead to the conclusion that other drugs should be tried first. Whether ziprasidone will cause torsade de pointes or increase the rate of sudden death is not yet known (see WARNINGS ). The efficacy of oral ziprasidone was established in short-term (4- and 6-week) controlled trials of schizophrenic inpatients (see CLINICAL PHARMACOLOGY ). In a placebo-controlled trial involving the follow-up for up to 52 weeks of stable schizophrenic inpatients, GEODON was demonstrated to delay the time to and rate of relapse. The physician who elects to use GEODON for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient. Ziprasidone is indicated for the treatment of acute manic or mixed episodes associated with bipolar disorder, with or without psychotic features. A manic episode is a distinct period of abnormally and persistently elevated, expansive, or irritable mood. A mixed episode is characterized by the criteria for a manic episode in conjunction with those for a major depressive episode (depressed mood, loss of interest or pleasure in nearly all activities). The efficacy of ziprasidone in acute mania was established in 2 placebo-controlled, double-blind, 3- week studies in patients meeting DSM-IV criteria for Bipolar I Disorder who currently displayed an acute manic or mixed episode with or without psychotic features (see CLINICAL PHARMACOLOGY ). The effectiveness of ziprasidone for longer-term use and for prophylactic use in mania has not been systematically evaluated in controlled clinical trials. Therefore, physicians who elect to use ziprasidone for extended periods should periodically re-evaluate the long-term risks and benefits of the drug for the individual patient (see DOSAGE AND ADMINISTRATION ). Acute Agitation in Schizophrenic Patients Ziprasidone intramuscular is indicated for the treatment of acute agitation in schizophrenic patients for whom treatment with ziprasidone is appropriate and who need intramuscular antipsychotic medication for rapid control of the agitation. The efficacy of intramuscular ziprasidone for acute agitation in schizophrenia was established in single-day controlled trials of schizophrenic inpatients (see CLINICAL PHARMACOLOGY ). Since there is no experience regarding the safety of administering ziprasidone intramuscular to schizophrenic patients already taking oral ziprasidone, the practice of co-administration is not recommended.
It is not not considered an addictive drug like cocaine best accutane 5 mg, heroin or alcohol because it does not produce the same compulsive drug-seeking behavior discount 10 mg accutane otc. However 10mg accutane visa, like addictive drugs, it produces greater tolerance in some users who take the drug repeatedly. These users must take higher doses to achieve the same results as they have had in the past. This could be an extremely dangerous practice because of the unpredictability of the drug effect on an individual. You may experience fear, anger, guilt, surprise, sadness, or relief. There is no right or wrong response to your HIV diagnosis. Remember you are not alone; many people have been where you are now. Having HIV can be difficult and will be stressful at times. Thankfully, recent medical advancements have made living with HIV more manageable. There are many issues to consider that can help make your journey easier. When coping with any medical condition, it is important to have someone to turn to for support. Unfortunately, the stigma that is often associated with HIV may make it more difficult for you to share your HIV diagnosis with loved ones. This is a personal decision with no right or wrong answer. Many people struggle with whether or not to share their HIV status with family or friends. Certainly you do not need to share your private information with everyone. However, it is important that you should not try to go it alone. Talking with loved ones about your HIV status may be stressful. People often cite fear of rejection, lack of understanding, or burdening family and friends as primary reasons not to disclose their diagnosis. If you choose to tell a trusted family member or friend, find a private time that is devoted to your discussion. Decide how much information you feel comfortable sharing regarding your illness and treatment. For instance, your loved one may have questions about the status of your treatment or how you contracted the virus. Remember, your loved one may need time to process this information. The initial talk will likely be the first of many discussions with your loved one as you both begin to learn more about living with HIV. It is important to consider that by not sharing your status you may be depriving yourself of much needed support. A very difficult question regarding disclosure is talking with a partner or spouse with whom you have had unprotected sexual contact. If they are advised of their possible exposure to the HIV virus, they can then be tested themselves. If they are not tested and have HIV, they may be at risk for progression of their disease to AIDS and death. Therefore, you should notify them as soon as you can. If, like some people, you feel unable to disclose your HIV status to a sexual partner, there are some alternatives.
Compulsions sometimes relate to obsessions cheap 20 mg accutane mastercard, but often they seem completely unrelated order accutane 10mg overnight delivery, for example a person with an obsession about harming someone may have a compulsion that involves counting buy accutane 40mg. Children with OCD have the same types of obsessions and compulsions as adolescents and adults with the disorder, but the issues with which they are concerned may differ. A young child may worry about getting sick from touching a doorknob, while a teenager or adult may worry specifically about catching AIDS from touching a doorknob. Approximately 20% of children with the disorder have a relative who is also a sufferer. It is not known whether a child with OCD will grow into an adult with OCD, but the number of adults with OCD suggest that many do not. Treatment of Obsessive Compulsive Disorder in children and adults is effective. It is common to use combination therapies for both (see p. Behavior therapy has proven to be very effective in the treatment of OCD. A form of behavior therapy found to be particularly effective in dealing with OCD is exposure and response therapy. In this type of therapy the patient is exposed to whatever he fears, and is subsequently encouraged to not engage in his compulsion for a period of time, which is increased by increments with each treatment. With cognitive therapy the goal is to change the irrational belief system of the sufferer, to get them to realize that even though their obsessive thoughts make them very anxious, they can be safely ignored. Swedo, the response rate of children 8-14 years old to the combination therapies of medication and Cognitive Behavioral Therapy is similar to the response rate in adults. Obsessive Compulsive Disorder is responsive to treatment, although that treatment may be hard work, for both child and parents. American Anxiety Disorders Association of America newsletter (Jan. A majority of children and teens with OCD also suffer with other anxiety disorders, depression and behavior disorders. Once thought to be a rare phenomenon, pediatric obsessive-compulsive disorder (OCD) has been found to be a fairly common condition affecting between 1% and 4% of young people. It also, more often than not, co-occurs with a variety of other disorders. Research has found that 58%-80% of children and adolescents with OCD also suffer from at least one other psychiatric diagnosis and between 30%-50% from two or more. Rates for specific comorbid disorders varies greatly from study to study. However, the rank order of diagnostic category remains fairly consistent with anxiety disorders (e. Examining anxiety disorders more specifically in pediatric OCD, one finds high rates of generalized anxiety disorder (20%), specific phobia (16%-36%), social anxiety disorder (7%-33%), panic disorder (18%-33%), and separation anxiety (4%-56%). In terms of depressive disorders, high rates of major depression (6%-62%) and dysthymia (8%-15%) are also found. Interestingly, several studies have found the onset of the depressive disorders followed the onset of the OCD, which could point to depression being a consequence of OCD in some cases and not a primary problem in-of-itself. Rate of separation anxiety was also found to be age sensitive with adolescents experiencing a considerably high rate yet lower than in children (35% versus 56%). High rates of other anxiety disorders were seen in both children and adolescents with no significant differences found between them. In a different study, Geller and colleagues examined children with a childhood onset of OCD, adolescents with a childhood onset of OCD, and adolescents with an adolescent onset of OCD. Pediatric OCD comorbidity is an important issue with possible treatment implications. In a third study, Geller and colleagues found that comorbidity might play a role in terms of medication treatment response and relapse rates. Whereas 75% of pediatric OCD sufferers without any coexisting conditions responded to paroxetine, response rates with comorbid attention deficit hyperactivity disorder, tic disorder, and oppositional defiant disorder were much lower (56%, 53%, and 39% respectively). In terms of relapse following discontinuation of paroxetine, increased rates were found in those having a comorbid condition.
10 of 10 - Review by F. Navaras
Votes: 264 votes
Total customer reviews: 264